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years for related and unrelated recipients, respectively. Two
year overall survival was 42% and disease-free survival was 36%,
with disease stages and cytogenetic risks being major determi-
nants for outcome. Patients transplanted in CR1 had 2-year
overall survivals of 40% after related and 57% after unrelated
HCT. We conclude that HCT from related and unrelated
donors after low-dose TBI is a promising treatment for elderly
patients and medically inﬁrm younger patients with AML not
eligible for conventional HCT.
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FEWER EARLY BACTERIAL AND VIRAL INFECTIONS FOLLOWING NON-
MYELOABLATIVE VS. MYELOABLATIVE CONDITIONING FOR ALLO-
TRANSPLANTATION
Bachanova, V., Brunstein, C., Burns, L.J., Miller, J.S., Tan, Y.,
van Burik, J., Weisdorf, D., Tomblyn, M. University of Minnesota, Divi-
sion of Hematology, Oncology, and Transplantation, Minneapolis, MN.
To examine the incidence and timing of infectious complications,
we reviewed 141 consecutive lymphoma patients receiving allogeneic
hematopoietic stem cell transplantation using either myeloablative
(MA) (n  65) or non-myeloablative (NMA) (n  76) conditioning.
The NMA cohort was older (48.4 vs 41.4 years, P .01), more often
given unrelated umbilical cord blood as a stem cell source (43% vs
9%, P .01), had comparable CMV seropositivity (39% vs 49%) and
39% had received a prior autologous transplant. All patients received
antimicrobial prophylaxis including an extended spectrum ﬂuoroquin-
olone, ﬂuconazole, and acyclovir in addition to weekly CMV surveil-
lance. The time to initial infection was determined for each patient to
analyze potential differences in types and time to onset of infection
between the cohorts. For this, patients were evaluated once in each of
three microbial categories bacterial, viral, and fungal (Table 1). Fatal
infections were uncommon and the incidence was similar in the MA
and NMA cohorts [MA: 12 (18%); NMA: 12 (16%)]. In the peri-
transplant period (day 0-30), the MA cohort had 2.2-fold greater
primary bacterial infections, but the risks of initial bacterial infection
were similar in the early (day 31-100) and late (day 101-365) post
transplant periods. Viral infections were twice as frequent in the MA
cohort during the peritransplant period though similar from day
30-100. Beyond day 100, the MA cohort again had 2-fold greater
primary viral infections. Fungal infections developed in approximately
10% of patients in both cohorts and the risks were similar during all
three time periods. These data demonstrate a signiﬁcantly greater
incidence of bacterial and viral peri-transplant infections using MA
conditioning though infectious mortality was similar using either
conditioning. Quicker engraftment and shorter periods of neutrope-
nia may explain in part the reduced incidence of initial peri-transplant
bacterial infections in the NMA cohort, but the pathophysiology
underlying the later infectious risks is uncertain. Immune reconstitu-
tion is delayed after both MA and NMA conditioning but protection
against infection appears similar using either treatment approach.
Future studies to correlate immune reconstitution with infections are
required to identify patients at greatest risk of later infections and to
design new strategies for their prevention.
Table 1. Incidence of Infections
Myeloablative Non-myeloablative P-Value
Bacterial
Day 0–30 49% (36–62) 22% (13–32) <.01
Day 31–100 47% (28–66) 48% (35–62) NS
Day 101–365 23% (0–45) 11% (0–22) NS
Viral
Day 0–30 18% (9–28) 9% (3–16) .08
Day 31–100 31% (17–45) 44% (32–56) NS
Day 101–365 44% (25–64) 21% (7–35) .05
Fungal
Day 0–30 12% (4–21) 9% (3–16) NS
Day 31–100 12% (3–21) 13% (5–22) NS
Day 101–365 10% (1–20) 17% (7–28) NS
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ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (ALLO HCT)
FOR METASTATIC BREAST CANCER (MBC)
Ueno, N.T.1, Rizzo, J.D.2, Cheng, Y.C.2, Childs, R.3, Stiff, P.J.3,
Demirer, T.4, Horowitz, M.M.2, Niederwieser, D.4 1The University of
Texas M.D. Anderson Cancer Center, Houston, TX; 2Medical College of
Wisconsin, Milwaukee, WI; 3Center for International Blood and Mar-
row Transplant Research (CIBMTR); 4The European Group for Blood
and Marrow Transplantation (EBMT).
We reviewed data on women who received allogeneic hema-
topoietic cell transplantation (HCT) for metastatic breast can-
cer at 16 centers participating in the CIBMTR and the EBMT
between 1992 and 2000. Probabilities of transplant-related mor-
tality (TRM), graft-vs-host disease (GVHD), disease relapse or
progression, progression-free survival (PFS), and overall sur-
vival were determined. Seventy-ﬁve patients were identiﬁed;
median age at transplantation was 41 years (range, 25-60).
Median follow-up time for survivors was 25 months (range,
3-64). Thirty-nine patients (52%) received myeloablative con-
ditioning regimens and 36 (48%) received reduced-intensity
conditioning (RIC) regimens. Nine of the RIC patients were
treated with a planned tandem autologous-allogeneic approach.
Patient characteristics were similar between the two groups
except that more patients in the RIC group (72%) had poor
pretransplant performance status than in the myeloablative
group (28%). More patients in the myeloablative group devel-
oped acute GVHD (44% vs 34% at 100 days), chronic GVHD
(36% vs. 8% at one year) and TRM (29% vs 7% at 100 days)
compared to RIC. Overall response rates (complete or partial
response) were 31% in the myeloablative group and 29% in the
RIC group. Eleven of 42 patients (26%) who underwent im-
mune manipulation (withdrawal of immunosuppression and/or
donor lymphocyte infusion) after transplantation had disease
control (complete, partial, minor, or stable response), providing
evidence of a graft-vs-tumor (GVT) effect. Overall survival at 2
yrs was 24% (15-35%) for all patients. PFS at 1 year was 23%
for myeloablative patients and 8% for RIC (excludes planned
tandem) patients. Development of acute GVHD after an RIC
regimen compared to no GVHD reduced the risk of relapse or
progression (RR 3.05, P  .03) in multivariate analysis, consis-
tent with a GVT effect, but this did not affect PFS. These
ﬁndings support development of innovative allotransplantation
approaches to exploit GVT effects for disease control while
minimizing TRM. Planned tandem autologous-allogeneic RIC
HCT, where probabilities of TRM and PFS at 2 years were 11%
and 44% respectively for a small number of patients in these
data, may represent such an alternative approach.
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HAEMOPOIETIC STEM CELL TRANSPLANTS FOR CHRONIC MYELOFI-
BROSIS—A REVIEW FROM THE ABMTRR
Nivison-Smith, I.1, Bradstock, K.F.2, Dodds, A.J.3, Durrant, S.4,
Ma, D.D.F.3, Szer, J.5 1Australasian Bone Marrow Transplant Recip-
ient Registry (ABMTRR), Darlinghurst, NSW, Australia; 2Westmead
Hospital, Westmead, NSW, Australia; 3St. Vincent’s Hospital, Darlin-
ghurst, NSW, Australia; 4Royal Brisbane Hospital, Brisbane, Queens-
land, Australia; 5Royal Melbourne Hospital, Parkville, Victoria, Aus-
tralia.
The Australasian Bone Marrow Transplant Recipient Registry
(ABMTRR) has been recording activity and outcome data for
haemopoietic stem cell transplants in Australia since 1992 and New
Zealand since 1998. Between 1992 and 2004 there were 50 hae-
mopoietic stem cell transplants for chronic myeloﬁbrosis in Aus-
tralia and 1 in New Zealand. Of these, 46 were allogeneic, 3
syngeneic and 2 autologous; 35 were male and 16 were female. The
median age at transplant was 48 with a range of 16 to 71. The
annual number of transplants for this indication is small but in-
creasing. In the ﬁve years 2000 to 2004, there were 33 transplants
for this indication compared to 14 in 1995-1999. Of the donors for
allogeneic transplants, 33 were HLA-identical siblings, 3 were
siblings or other relatives with 1 HLA mismatch and 10 were
unrelated volunteers. Within the allogeneic transplants performed
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in 2000 and later, 6 used reduced intensity conditioning. Two
patients had persistent disease, four died prior to 30 days post
transplant and it was assumed that all others achieved remission.
Four allogeneic and one autologous recipient relapsed, all within 3
years post transplant. For allogeneic transplants, the 5-year overall
survival probability was 48% with lower and upper bounds of 31%
and 65%, which is comparable to the ﬁnding of 47% in a recent
EBMT study [1]. Transplant related mortality at 100 days was
19.6%. There were 16 deaths in the ﬁrst year post transplant
among allogeneic and syngeneic recipients, from infection (7),
GVHD (4), organ failure (3) and persistent disease (2). Both au-
tologous recipients died, from septicaemia at 6 months and relapse
at 2.3 years post transplant. The ABMTRR is an important na-
tional data resource which enables accurate and timely analysis of
transplant activity and outcome, particularly for rare indications
that have relatively small numbers.
1. Guardiola P, et al. Allogeneic stem cell transplantation for
agnogenic myeloid metaplasia: a European Group for Blood and
Marrow Transplantation, Societe Francaise de Greffe de Moelle,
Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred
Hutchinson Cancer Research Center collaborative study. Blood.
1999;93:2831-2838.
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LOW INCIDENCE OF ACUTE GRAFT VERSUS HOST DISEASE AND RE-
DUCED EARLY MORTALITY IN CP-CML PATIENTS TRANSPLANTED US-
ING CSA, MTX AND MP AS IMMUNOPROPHYLAXIS
Funke, V.M., Setubal, D.C., Ruiz, J., Lima, D.H., Bonﬁm, C.M.,
Bitencourt, M.A., Zanis-Neto, J., de Medeiros, C.R., Pasquini, R.
Hospital de Clı´nicas-Federal University of Parana, Curitiba, Parana,
Brazil.
Signiﬁcant early transplant related mortality is one of the factors
that have impacted the reduction of transplants for CML, espe-
cially in the imatinib era. However, curative potential of bone
marrow transplantation has to be taken into consideration, espe-
cially for young high risk patients. Patients and Methods: We
report here long-term results from a single center experience of
166 patients submitted to bone marrow transplantation for chronic
phase CML from 1990 to 2004. All patients received marrow from
sibling HLA identical donors, and used BU  CY as the condi-
tioning regimen and cyclosporine, methotrexate and a short course
of MP (1 mg/kg/day from day 14 to day 28, then tapered 20%
per week) as immunoprophylaxis. Male: 92; female 74. Median age
was 33 years (range 6-51). Median duration of disease was 20
months (4-87). Univariate and multivariate analysis of risk factors
for survival were performed. Age, disease duration before trans-
plant, female donor  male patient, time of engraftment, acute
GVHD and chronic GVHD were analyzed risk factors. Results:
Mortality before day 100 was 8%. Grade III-IV acute GVHD
occurred in only 7% of the patients. From 153 patients who survived
more than 100 days, 63 (38%) developed extensive chronic graft-
versus-host disease. Median survival was 2498 days (58-5391). Overall
survival and estimated disease free survival in 14 years was 71%. Only
the presence of grade III-IV of acute and extensive chronic graft-
versus-host disease were identiﬁed as independent risk factors for
survival. Causes of death included: c-GVHD (13%), infections (9%)
and progressive disease (7%). Conclusions: The addition of MP to
the immunoprophylaxis regimen has effectively reduced the incidence
of grade III-IV acute GVHD and early transplant related mortality.
No inﬂuence was seen on chronic GVHD incidence, overall survival
or disease free survival.
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PREDICTIVE FACTORS AND IMPACT OF FULL DONOR T-CELL CHIMER-
ISM AFTER REDUCED INTENSITY CONDITIONING (RIC) ALLOGENEIC
STEM CELL TRANSPLANTATION (ALLO-SCT)
Mohty, M.1, Avinens, O.2, Faucher, C.1, Furst, S.1, Viens, P.1,
Gastaut, J.-A.1, Eliaou, J.-F.2, Blaise, D.1 1Institut Paoli-Calmettes,
Marseille, France; 2CHU de Montpellier, Montpellier, France.
The kinetics of lineage-speciﬁc chimerism proved to be an im-
portant issue after RIC allo-SCT. Here, we investigated the impact
of different factors on the establishment of full donor CD3T cell
chimerism (TCC) in a series of 102 patients receiving RIC allo-
SCT from an HLA-identical sibling. 65 patients received an ATG-
based RIC regimen (ﬂudarabine, busulfan and ATG), 14 patients
received a low dose TBI-based RIC (2 Gy), while the remaining 23
patients received an association of ﬂudarabine, busulfan and total
lymphoid irradiation (TLI; 1.7 Gy). At day 30, 30% (95% CI,
21-39%) of patients achieved a full TCC in the peripheral blood.
At day 90, 77% (95% CI, 69-85%) had a full donor TCC. In
univariate analysis, none of the patient, graft, RIC type, or disease
characteristics could be predictive of establishment of an early full
donor TCC at day 30. However, the group of 31 patients who
achieved a full donor TCC by day 30, experienced a signiﬁcantly
higher incidence of grade 2-4 acute GVHD, in comparison to the
group of 71 patients who were still in mixed TCC at day 30
(cumulative incidence, 61% vs. 35%; P  .01). When looking for
predictive factors for full donor TCC at day 90, univariate analysis
showed that diagnosis category, the RIC type (ATG, TBI or
TLI-based RIC), a female donor, CD34 cell dose, and CD4 T
cell dose, were signiﬁcant or had a trend towards signiﬁcant asso-
ciation with establishment of full donor TCC by day 90. In mul-
tivariate analysis, a diagnosis other than a myeloid malignancy, was
the strongest parameter signiﬁcantly predictive of establishment of
full TCC at day 90 (P .007; OR 3.82; 95% CI, 1.4-10.1). Most
importantly, the delayed establishment of full donor TCC in pa-
tients with myeloid malignancies translated towards a worsened
PFS (P  .06) in the group of 15 patients who did not achieve full
donor TCC at day 90 as compared to the group of 26 patients who
achieved a full donor TCC. This worsened PFS was due to a
signiﬁcantly higher incidence of leukemia relapse among these 15
patients (6 relapses; 40%) as compared to none in the other group
of 26 patients (P  .002). Overall, we conclude that cautious
monitoring of the levels of donor TCC is mandatory after RIC
allo-SCT, because this can improve patient outcomes through
identiﬁcation of patients at risk for acute GVHD, and disease
progression, and guidance of early interventions with immunosup-
pressive drugs or DLI aimed at obviating these complications.
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PENTOSTATIN, TBI AND EXTRACORPOREAL PHOTOPHERESIS FOR RE-
DUCED-INTENSITY PREPARATION: SINGLE CENTER ADAPTATION OF
THE TUFTS EXPERIENCE
Abboud, C.N., Liesveld, J.L., Bernstein, S.H., Friedberg, J.,
Ifthikharuddin, J.J., Constine, L.S., Kaplan, K.L., Wedow, L.A.,
Nichols, D.D., Oliva, J., Etter, M., Phillips, G.L. James P Wilmot
Cancer Center, University of Rochester, Rochester, NY.
Conditioning regimens used in reduced intensity transplants are
designed to optimize immune suppression to allowing for prompt
engraftment and robust graft versus tumor effect. The Tufts reg-
imen (Miller KB, et al. Bone Marrow Transplant 2004;34:881) has a
reduced incidence of GVHD while demonstrating disease response
using extracorporeal photopheresis (ECP), pentostatin 4 mg/m2/
day 2 and a reduced dose of total body irradiation (TBI: 600 cGy
given in 3 fractions). We treated 45 patients with a minimum of 6
months follow up, median age of 55 years (27-67); 33 patients were
50 years or older; 25 received sibling and 20 an unrelated donor
(UD) transplant. All but one sibling transplant was a 6/6 match,
whereas 8/20 UD transplants involved mismatched loci. GVHD
prophylaxis consisted of tacrolimus and short course methotrexate
in 43, tacrolimus/MMF in 1 and tacrolimus/sirolimus in 1. Seven-
teen patients had AML, 3 MDS, 2 ALL, 2 CML, 11 CLL, 8 NHL,
1 HD and 1 lymphoplasmacytic lymphoma. Eight of the 45 had
prior stem cell transplantation. The median number of CD34
cells infused was 4.54 million/kg. Nine patients were transplanted
in CR or early disease phase. Five patients died before anticipated
neutrophil recovery, 2 had no neutrophil nadir and median time to
neutrophil engraftment was 14.5 days, and platelets recovered in
18.7 days. Donor chimerism at 30 days by VNTRs was 94% (range
34%-100%). The overall day 100 survival was 69% (31/45), with
80% (20/25) of sibling graft recipients alive and 55% (11/20) of
UD recipients still living. Twelve patients developed regimen
related toxicity. In ﬁve this manifested as ARDS or multiorgan
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